Ching-Chich Weng

Dr. Ching-Chich Weng

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PWPei-Chen Wang
Pei-Chen Wang
CWChing-Chich Weng
Ching-Chich Weng
YHYou-Syuan Hou
You-Syuan Hou
SJShu-Fang Jian
Shu-Fang Jian
KFKuan-Te Fang
Kuan-Te Fang
KCKuang-hung Cheng
Kuang-hung Cheng
VCAM-1 (CD106), a transmembrane glycoprotein, was first reported to play an important role in leukocyte adhesion, leukocyte transendothelial migration and cell activation by binding to integrin VLA-1 (α4β1). In the present study, we observed that VCAM-1 expression can be induced in many breast cancer epithelial cells by cytokine stimulation in vitro and its up-regulation directly correlated with advanced clinical breast cancer stage. We found that VCAM-1 over-expression in the NMuMG breast epithelial cells controls the epithelial and mesenchymal transition (EMT) program to increase cell motility rates and promote chemoresistance to doxorubicin and cisplatin in vitro. Conversely, in the established MDAMB231 metastatic breast cancer cell line, we confirmed that knockdown of endogenous VCAM-1 expression reduced cell proliferation and inhibited TGFβ1 or IL-6 mediated cell migration, and increased chemosensitivity. Furthermore, we demonstrated that knockdown of endogenous VCAM-1 expression in MDAMB231 cells reduced tumor formation in a SCID xenograft mouse model. Signaling studies showed that VCAM-1 physically associates with CD44 and enhances CD44 and ABCG2 expression. Our findings uncover the possible mechanism of VCAM-1 activation facilitating breast cancer progression, and suggest that targeting VCAM-1 is an attractive strategy for therapeutic intervention.

Verified
Journal Article
Open access
PDF file
MHMei Jen Hsieh
Mei Jen Hsieh
TCTai-Jan Chiu
Tai-Jan Chiu
YLYu Chun Lin
Yu Chun Lin
CWChing-Chich Weng
Ching-Chich Weng
YWYu-Ting Weng
Yu-Ting Weng
KCKuang-hung Cheng
Kuang-hung Cheng
Pancreatic cancer (PC) is a highly lethal malignancy due to the cancer routinely being diagnosed late and having a limited response to chemotherapy. Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic malignant tumor, representing more than 85% of all pancreatic cancers. In the present study, we characterized the phenotypes of concomitant P53 and APC mutations in pancreatic neoplasms driven by the oncogene KRAS in genetically modified mice (GEMM). In this GEMM setting, APC haploinsufficiency coupled with P53 deletion and KRASG12D activation resulted in an earlier appearance of pancreatic intraepithelial neoplasia (PanIN) lesions and progressed rapidly to highly invasive and metastatic PDAC. Through a microarray analysis of murine PDAC cells derived from our APC-deficient PDAC model, we observed that APC loss leads to upregulated CD34 expression in PDAC. CD34 is a member of a family of single-pass transmembrane proteins and is selectively expressed in hematopoietic progenitor cells, vascular endothelial cells, interstitial precursor cells, and various interstitial tumor cells. However, the functional roles of CD34 in pancreatic cancer remain unclear. Thus, in this study, we explored the mechanisms regarding how CD34 promotes the deterioration of pancreatic malignancy. Our results demonstrated that the increased expression of CD34 induced by APC inactivation promotes the invasion and migration of PDAC cells, which may relate to PDAC metastasis in vivo. Collectively, our study provides first-line evidence to delineate the association between CD34 and the APC/Wnt pathway in PDAC, and reveals the potential roles of CD34 in PDAC progression.

2 September 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CWChing-Chich Weng
Ching-Chich Weng
YLYu-Chun Lin
Yu-Chun Lin
KCKuang-hung Cheng
Kuang-hung Cheng
Pancreatic cancer is often treatment-resistant, with the emerging standard of care, gemcitabine, affording only a few months of incrementally-deteriorating survival. Reflecting on the history of failed clinical trials, genetically engineered mouse models (GEMMs) in oncology research provides the inspiration to discover new treatments for pancreatic cancer that come from better knowledge of pathogenesis mechanisms, not only of the derangements in and consequently acquired capabilities of the cancer cells, but also in the aberrant microenvironment that becomes established to support, sustain, and enhance neoplastic progression. On the other hand, the existing mutational profile of pancreatic cancer guides our understanding of the disease, but leaves many important questions of pancreatic cancer biology unanswered. Over the past decade, a series of transgenic and gene knockout mouse modes have been produced that develop pancreatic cancers with features reflective of metastatic pancreatic ductal adenocarcinoma (PDAC) in humans. Animal models of PDAC are likely to be essential to understanding the genetics and biology of the disease and may provide the foundation for advances in early diagnosis and treatment.

Verified
Journal Article
Open access
PDF file
MHMei-Jen Hsieh
Mei-Jen Hsieh
CWChing-Chich Weng
Ching-Chich Weng
YLYu-Chun Lin
Yu-Chun Lin
CWChia-Chen Wu
Chia-Chen Wu
LCLi-Tzong Chen
Li-Tzong Chen
KCKuang-hung Cheng
Kuang-hung Cheng
Pancreatic cancer (PC) is the seventh leading cause of cancer death worldwide, and remains one of our most recalcitrant and dismal diseases. In contrast to many other malignancies, there has not been a significant improvement in patient survival over the past decade. Despite advances in our understanding of the genetic alterations associated with this disease, an incomplete understanding of the underlying biology and lack of suitable animal models have hampered efforts to develop more effective therapies. LKB1 is a tumor suppressor that functions as a primary upstream kinase of adenine monophosphate-activated protein kinase (AMPK), which is an important mediator in the regulation of cell growth and epithelial polarity pathways. LKB1 is mutated in a significant number of Peutz–Jeghers syndrome (PJS) patients and in a small proportion of sporadic cancers, including PC; however, little is known about how LKB1 loss contributes to PC development. Here, we report that a reduction in Wnt/β-catenin activity is associated with LKB1 tumor-suppressive properties in PC. Remarkably, in vivo functional analyses of β-catenin in the Pdx-1-Cre LKB1L/L β-cateninL/L mouse model compared to LKB1 loss-driven cystadenoma demonstrate that the loss of β-catenin impairs cystadenoma development in the pancreas of Pdx-1Cre LKB1L/L mice and dramatically restores the normal development and functions of the pancreas. This study further determined the in vivo and in vitro therapeutic efficacy of the β-catenin inhibitor FH535 in suppressing LKB1 loss-driven cystadenoma and reducing PC progression that delineates the potential roles of Wnt/β-catenin signaling in PC harboring LKB1 deficiency.

3 April 2023
Verified
Other
Open access
SJShu-Fang Jian
Shu-Fang Jian
CHChang-Chun Hsiao
Chang-Chun Hsiao
SCShin-Yi Chen
Shin-Yi Chen
CWChing-Chich Weng
Ching-Chich Weng
TKTzu-Lei Kuo
Tzu-Lei Kuo
KCKuang-hung Cheng
Kuang-hung Cheng
XLSX file - 91K, List of complete protein identification results from LKB1 IP complex by LC MS/MS analysis in A549 and H460 LKB1 cells.

3 April 2023
Verified
Other
Open access
SJShu-Fang Jian
Shu-Fang Jian
CHChang-Chun Hsiao
Chang-Chun Hsiao
SCShin-Yi Chen
Shin-Yi Chen
CWChing-Chich Weng
Ching-Chich Weng
TKTzu-Lei Kuo
Tzu-Lei Kuo
KCKuang-hung Cheng
Kuang-hung Cheng
PDF file - 105K, Decreased expression of CD44 in LKB1 proficient lung cancer cells by immunofluorescent analysis.